This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus

This study has been completed.
Bristol-Myers Squibb
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: December 7, 2005
Last updated: November 16, 2016
Last verified: November 2016
The purpose of this clinical research study is to learn if BMS-512148 is effective in controlling blood sugar levels as determined by HbA1c and fasting plasma glucose in patients who have been diagnosed with Type 2 diabetes. Patients should first try to control their diabetes with diet and exercise and should not have previously been treated for their diabetes (very short periods of time are acceptable). The safety of BMS512148 will also be studied

Condition Intervention Phase
Type 2 Diabetes Drug: dapagliflozin Drug: placebo Drug: metformin Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Trial to Evaluate the Safety and Efficacy of BMS-512148 as Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Are Treatment Naive And Have Inadequate Glycemic Control on Diet and Exercise

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Mean change from baseline in HbA1c compared to placebo. [ Time Frame: at 12 weeks ]

Secondary Outcome Measures:
  • Mean change from baseline in fasting plasma glucose, evaluate proportion of subjects who achieve a therapeutic response (HbA1c <7%); change from baseline in urinary glucose excretion [ Time Frame: at Weeks 6 and 12 ]

Enrollment: 389
Study Start Date: December 2005
Study Completion Date: February 2007
Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Drug: dapagliflozin
Tablets, Oral, 2.5 mg, Once daily, 12 weeks.
Experimental: Arm 2 Drug: dapagliflozin
Tablets, Oral, 5 mg, Once daily, 12 weeks.
Experimental: Arm 3 Drug: dapagliflozin
Tablets, Oral, 10 mg, Once daily, 12 weeks.
Experimental: Arm 4 Drug: dapagliflozin
Tablets, Oral, 20 mg, Once daily, 12 weeks.
Experimental: Arm 5 Drug: dapagliflozin
Tablets, Oral, 50 mg, Once daily, 12 weeks.
Placebo Comparator: Arm 6 Drug: placebo
Tablets, Oral, 0 mg, Once daily, 12 weeks.
Active Comparator: Arm 7 Drug: metformin
Tablets, Oral, >/= 1500 mg, Once daily, 12 weeks.


Ages Eligible for Study:   18 Years to 79 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with Type 2 diabetes mellitus with inadequate glycemic control on diet and exercise. HbA1c >= 7% and <=10%.
  • Patient either has not been previously treated with antihyperglycemic medication or has been treated for <30 days since diagnosis and has received less than 3 consecutive doses or 7 non-consecutive doses in the last 30 days.
  • C-peptide > 1.0 ng/ml
  • Body Mass Index <= 40 kg/m2
  • Serum creatinine < 1.5 mg/dL for men or < 1.4 mg/dL for women.
  • No overt proteinuria (microalbumin/creatinine ratio must be <300 mg/g

Exclusion Criteria:

  • Unstable renal disease
  • Patients with significant liver disease including chronic active hepatitis
  • Within the last 6 months has had any of the following cardiovascular event: myocardial infarction, unstable angina, unstable CHF,NYHA Class III or IV CHF, TIA, unstable arrhythmia or cardiac revascularization surgery.
  • Subjects with clinically significant anemia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00263276

  Show 145 Study Locations
Sponsors and Collaborators
Bristol-Myers Squibb
Study Director: Bristol Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: AstraZeneca Identifier: NCT00263276     History of Changes
Other Study ID Numbers: MB102-008
Study First Received: December 7, 2005
Last Updated: November 16, 2016

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases processed this record on September 21, 2017